The ASCENT-03 trial allowed control arm patients to receive sacituzumab govitecan upon progression. This ethical choice complicates overall survival interpretation, as many control patients ultimately got the active drug, making direct comparison with non-crossover trials like TROPION-Breast02 difficult.
Unlike ASCENT-03, which required a six-month treatment-free interval, the TROPION-Breast02 trial for datopotamab deruxtecan included patients with immediate relapse after prior therapy. This provides crucial evidence for treating a high-need population with a very poor prognosis, a group often excluded from pivotal trials.
The apparent lack of survival benefit for datopotamab in North American patients is likely an artifact. Better access to other effective antibody-drug conjugates after progression in the control arm diluted the survival advantage, highlighting how regional care standards can confound trial outcomes.
Trop-2 antibody-drug conjugates (ADCs) outperform chemotherapy in metastatic triple-negative breast cancer regardless of the patient's Trop-2 expression level. While higher expression correlates with better response, the ADCs are superior even in low-expressing tumors, making it an ineffective selection tool versus chemo.
Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.
Current first-line ADC trials for metastatic TNBC largely excluded patients who relapsed after receiving the KEYNOTE-522 neoadjuvant chemo-immunotherapy regimen. This timing mismatch creates a critical evidence gap for an increasingly common clinical scenario, forcing clinicians to rely on real-world data.